News
-
-
PRESS RELEASE
Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
Valneva SE reports solid full year 2024 results exceeding growth targets. Financial outlook for 2025 includes strong revenue growth and strategic investments. Key milestones and financial information discussed -
-
-
PRESS RELEASE
Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
Valneva receives marketing authorization in the UK for the world's first chikungunya vaccine, IXCHIQ®. Single-dose vaccine for individuals 18+ provides rapid and strong immune response -
-
-
-
-